Viyash Scientific Reports Record Q4 FY26 Results: EBITDA Exceeds Rs 200 Cr
Viyash Scientific Limited, formerly known as Sequent Scientific Limited, announced its financial results for the period ending March 31, 2026. The company, which operates across Formulations, APIs, and CDMO Services for human and animal health, reported that Q4 FY26 marked the strongest quarter in the company's history.The consolidated financial highlights show significant year-over-year growth across key metrics.
| Metric | Q4 FY26 (₹ in millions) | Q4 FY25 (₹ in millions) | Growth % | FY26 (₹ in millions) | FY25 (₹ in millions) | Growth % |
|---|---|---|---|---|---|---|
| Revenues | 9,200 | 7,723 | 19.1% | 34,203 | 30,068 | 13.8% |
| EBITDA* | 2,001 | 1,221 | 63.9% | 7,025 | 4,400 | 59.6% |
| EBITDA*% | 21.7% | 15.8% | 20.5% | 14.6% | - | - |
| PAT | 664 | -322 | 305.5% | 2,246 | 158 | 1334.0% |
EBITDA* refers to EBITDA excluding ESOP costs.
Dr Hari Babu Bodepudi, Managing Director and Group CEO of Viyash Scientific, stated that Fiscal Year 2026 was a transformative year for the company. He noted that Q4 marked a significant milestone, with merger synergies starting to reflect meaningfully in the financial performance.
"The integrated platform has strengthened execution, improved operating leverage, and enhanced our resilience amidst ongoing geopolitical and maritime disruptions," Dr Bodepudi commented. He added that the company continues to navigate these challenges through disciplined asset utilization, cost controls, and agile pricing strategies. Looking ahead, the group aims to leverage its product pipeline and growth roadmap. Furthermore, the company, which maintains a significantly deleveraged balance sheet, is actively evaluating selective inorganic opportunities to strengthen its platform and create long-term value.
Viyash Scientific Limited is an integrated pharmaceutical company globally among the top-25 Animal Health companies. It possesses a rich portfolio of formulations and APIs for human and veterinary use, serving customers in over 100 countries. The company has manufacturing, R&D, and distribution operations across India, Spain, Brazil, Turkey, and the USA, with approvals from international regulatory bodies including USFDA, EUGMP, WHO, and TGA.
VIYASH Stock Price Movement
On Tuesday, shares of Viyash Scientific Limited edged higher, closing at ₹228.73 after gaining 1.12% on the day. The stock settled on strong interest, handling a total traded volume of 1.19 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.